Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myeloma

Adam Sperling • 13 Jun 2022
EHA 2022
Multiple Myeloma PHE885

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, explains how the PHE885 CAR-T construct differs from existing BCMA-directed CAR-T therapies and highlights the results of a Phase I trial evaluating this product at different dose levels (NCT04318327). Overall, the study reported early evidence of promising activity and expansion of the CAR-Ts in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Adam Sperling

1:48
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
Adam Sperling • 27 Sep 2023
1:58
Clonal hematopoiesis in multiple myeloma and implications for therapy
Adam Sperling • 27 Sep 2023
2:05
Novel CAR-T constructs being explored in myeloma: T-Charge platform
Adam Sperling • 27 Sep 2023
1:53
PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myeloma
Adam Sperling • 4 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals